Skip to content

Surgical treatment of hepatoblastoma by near-infrared fluorescence imaging with indocyanine green

Surgical treatment of hepatoblastoma by near-infrared fluorescence imaging with indocyanine green

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062428
Enrollment
Unknown
Registered
2022-08-05
Start date
2022-08-31
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatoblastoma

Interventions

Sponsors

Capital Institute of Pediatrics
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Those patients who are definitely diagnosed as hepatoblastoma; 2. Patients without lung metastasis 4. The patients who are older than 0 and younger than 18 have no sex restriction; 5. Patients tolerating general anesthesia, ASA anesthesia grade below 3, without severe cardiopulmonary and cerebral diseases; 6. Patients who agree to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with unresectable hepatoblastoma; 2. Patients allergic to indocyanine green or iodine; 3. The researchers believe that the subjects may not be able to complete the study or comply with the requirements of the study (due to management or other reasons).

Design outcomes

Primary

MeasureTime frame
Secondary surgery;Number of liver lesions detected;R0 resection rate;Lung metastasis of tumor;

Secondary

MeasureTime frame
Postoperative complication index;

Countries

China

Contacts

Public ContactLong Li

Capital Institute of Pediatrics

lilong23@126.com+86 13001914151

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026